Elicio Therapeutics Inc ELTX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Trading Information
- Previous Close Price
- $1.92
- Day Range
- $1.85–1.97
- 52-Week Range
- $1.71–16.00
- Bid/Ask
- $1.78 / $2.00
- Shares Outstanding
- 26.28M
- Market Cap
- $50.46M
- Volume/Avg
- 175,962 / 512,546
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Elicio Therapeutics Inc is a clinical-stage biotechnology company advancing novel immunotherapies for the treatment of cancer, including mKRAS-positive pancreatic cancer, colorectal cancer (CRC), lung cancer, and other mKRAS-positive cancers. The Company focuses on developing effective, off-the-shelf immunotherapies using its proprietary Amphiphile (AMP) technology, which aims to enhance the education, activation, and amplification of cancer-specific T cells to promote durable cancer immunosurveillance. Its clinical pipeline includes ELI-002 7P, a lymph node-targeted cancer immunotherapy currently being evaluated in a Phase 2 study for mKRAS pancreatic ductal adenocarcinoma (PDAC), a common form of pancreatic cancer.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- 33
- Website
- https://www.elicio.com
Valuation
|
Metric
|
ELTX
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
ELTX
|
|---|---|
Quick Ratio | 2.55 |
Current Ratio | 2.77 |
Interest Coverage | −23.39 |
Quick Ratio
ELTX
Profitability
|
Metric
|
ELTX
|
|---|---|
Return on Assets (Normalized) | −128.98% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | −199.61% |
Return on Assets
ELTX
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|%<%V&pM | LOCK|JC#Kp | $128B | |||
| Moderna Inc
MRNA
| LOCK|mkk?Qh< | LOCK|@fh | $76B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|!r?@#@@ | LOCK|S!<Wd | $76B | |||
| argenx SE ADR
ARGX
| LOCK|FjvLyD | LOCK|%&b | $57B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|&>!K&wL | LOCK|m@! | $41B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|>!@%LG | LOCK|l??% | $29B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|Lj^ss^f | LOCK|HLkh | $25B | |||
| BioNTech SE ADR
BNTX
| LOCK|NmMv$$h | LOCK|hJb | $24B | |||
| Incyte Corp
INCY
| LOCK|#@BmP!? | LOCK|BG | $23B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|<H>!R%J | LOCK|^<F | $15B |
United States